Establishing Mouse Models for Zika Virus-induced Neurological Disorders Using Intracerebral Injection Strategies: Embryonic, Neonatal, and Adult
April 26th, 2018
8.2K views
Here we describe a method for establishing a model of Zika virus-induced microcephaly in mouse. This protocol includes methods for embryonic, neonatal, and adult-stage intracerebral inoculation of the Zika virus.
Overview
This study presents a method for creating in vivo models of Zika virus infection in the brain using a mouse model. The primary focus is on understanding the pathology and mechanisms of Zika virus-induced microcephaly at various developmental stages, which has implications for therapies and diagnostics.
Key Study Components
Area of Science
- Neuroscience
- Virology
- In vivo models
Background
- Zika virus infection is linked to microcephaly in fetuses.
- Understanding viral mechanics in the brain is crucial for addressing neurodevelopmental disorders.
- This technique can also extend to other flavivirus infections, like dengue.
Purpose of Study
- To establish a reliable method for studying Zika virus infections in the brain.
- To investigate the effects of the virus at embryonic, neonatal, and adult stages.
- To explore implications for therapy and diagnosis of associated disorders.
Methods Used
- A surgical method for intracerebral inoculation of Zika virus in mouse models.
- The primary biological model involves injecting embryos, neonatal pups, and adult mice.
- Important steps include preparing injection syringes, anesthetizing subjects, and injecting Zika virus into specified brain regions.
- Monitoring recovery and ensuring sterile conditions during surgical procedures are emphasized.
Main Results
- The technique allows for controlled infection of the brain, facilitating detailed study of viral pathogenesis.
- Significant insights into the development of neurodevelopmental issues related to Zika infection are anticipated.
- Potentially applicable to other flavivirus models enhances the method's versatility.
Conclusions
- This study establishes a foundational protocol for investigating Zika virus impact on brain development.
- Insights gained may enable advancements in understanding and treating Zika-related disorders.
Frequently Asked Questions
What are the advantages of this model for studying Zika virus?
The model allows precise control of viral inoculation in various developmental stages and can yield insights into the pathology of Zika virus infections.
How is the biological model implemented?
The model involves injecting Zika virus into the brains of embryos, neonatal pups, or adult mice to study the disease's progression and effects.
What types of data are obtained from this method?
Data obtained may include viral load, developmental outcomes, and neurodevelopmental changes associated with Zika infection.
What are the limitations of this method?
Considerations include the invasive nature of the procedure and ensuring anesthetic adequacy during surgery to minimize risks to the animals.
How can this technique be adapted for other infections?
By modifying virus strains used or adjusting injection protocols, this method can be adapted to study other flavivirus infections, such as dengue.
What is the significance of studying Zika virus in the brain?
Understanding the viral mechanisms in the brain is crucial for developing interventions to address microcephaly and other neurodevelopmental issues associated with infection.
Executive Industry Relevance
Establishing robust mouse models for Zika virus-induced neurological disorders enables targeted interrogation of viral pathogenesis across developmental stages. This approach supports predictive confidence in understanding neurodevelopmental risk and informs early-stage therapeutic hypothesis testing. The method's reproducibility and adaptability position it as a foundational tool for portfolio triage in neurovirology research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic de-risking by modeling direct Zika virus infection in embryonic, neonatal, and adult mouse brains.
- Supports functional target validation by allowing precise localization and timing of viral exposure.
- Facilitates hypothesis-driven studies on neurodevelopmental outcomes and viral pathogenesis.
Screening & Assay Development
- Provides a validated in vivo system for downstream evaluation of antiviral candidates or neuroprotective interventions.
- Standardizes infection protocols to ensure reproducibility and quantitative assessment of viral replication and pathology.
- Enables scalable preparation of disease-relevant models for compound screening and mechanistic studies.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints by modeling microcephaly and brain abnormalities observed in human Zika infection.
- Supports continuity from discovery through preclinical validation by enabling longitudinal studies of infection and intervention.
- Provides a platform for risk-adjusted advancement decisions based on translational biomarker readouts.
Pipeline & Workflow Integration
This intracerebral injection strategy integrates into the discovery-to-preclinical continuum, enabling early mechanistic studies and supporting lead identification for neurovirology portfolios.
- Discovery Biology: Facilitates hypothesis testing on Zika-induced neuropathology and viral replication dynamics.
- Screening: Delivers reproducible, quantitative infection models for evaluating candidate interventions.
- Analytics: Supports measurement of viral titers, immunolabeling, and neurodevelopmental outcomes for comparative analysis.
- Translational Research: Models human-relevant neurological sequelae, supporting biomarker alignment and preclinical validation.
- Enterprise Reuse: Adaptable to other flaviviruses, expanding utility across neuroinfectious disease research pipelines.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neurovirology target validation.
- Operational Value: Standardizes in vivo infection protocols for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by enabling early biological de-risking.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuroinfectious disease programs.
Implementation Considerations
- Requires expertise in stereotaxic surgery and in vivo virology techniques.
- Demands access to microinjection instrumentation and controlled recovery environments.
- Necessitates rigorous cross-team standardization of surgical and analytical protocols.
- Adaptable across developmental stages and potentially to other neurotropic viruses.
- Limitations include the non-physiological route of infection and need for appropriate controls.
Biopharma FAQs
Why does null hypothesis testing matter for Zika intracerebral infection models?
Null hypothesis testing enables rigorous evaluation of whether observed neurological outcomes are specifically attributable to Zika virus infection, supporting target validation and mechanistic clarity in neurovirology research.
How does independent variable isolation fit the embryonic and neonatal injection workflow?
Isolating the timing, location, and dose of Zika virus inoculation allows precise attribution of developmental effects, strengthening the predictive value of the model for discovery-stage studies.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative readouts such as viral titers, immunolabeling, and neurodevelopmental assessments enable comparative analysis of infection severity and intervention efficacy across experimental groups.
Why are replication requirements critical for cross-functional collaboration in Zika mouse models?
Standardized and reproducible surgical and analytical protocols ensure that results can be reliably compared and validated across teams, facilitating collaborative advancement of neurovirology programs.
Which statistical analysis capabilities are required before implementing TCID50 assays in this workflow?
Robust statistical analysis is needed to interpret TCID50 assay results, enabling accurate quantification of viral replication and supporting data-driven decision-making in preclinical research.
Chapters in this video
0:04
Title
1:07
Intracerebral Zika Virus Inoculation in Embryos
4:02
Intracerebral Zika Virus Inoculation in Neonates
6:06
Intracerebral Zika Virus Inoculation in Adult Mice
7:53
Results: Representative Histology in ZIKV-inoculated Embryos, Neonates, and Adult Mice
8:57
Conclusion
